ACS 67
目录号 : GC10623
An H2S-releasing latanoprost analog
Cas No.:1088434-86-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
ACS 67 is an analog of latanoprost acid.
Latanoprost, an F-series prostaglandin (PG) analog, has been approved for use as an ocular hypotensive drug for the treatment of glaucoma clinically. Latanoprost is an isopropyl ester, a prodrug form which is converted to free latanoprost acid by endogenous esterase enzymes.
In vitro: In previous study, ACS 67 was found to be able to increase the reduced glutathione levels in normotensive pigmented rabbits significantly after single administration in a dose-dependent manner. Furthermore, in glaucomatous pigmented rabbits after repeated 5-day administration, ACS 67 could also increase the GSH levels when compared with latanoprost. In addition, it was found that ACS 67 could significantly increase the cGMP levels in glaucomatous pigmented rabbits and these data with the combination supported that the increase of cGMP was due to the sulfurated moiety of ACS 67. Moreover, the tolerability was measured in New Zealand albino rabbits at three different concentrations of ACS 67, and results indicated that ACS 67 was very well tolerated in Draize test [1].
In vivo: So far, there in no animal in vivo data reported.
Clinical trial: Up to now, ACS 67 is still in the preclinical development stage.
Reference:
[1] E. Perrino, C. Uliva, C. Lanzi, et al. New prostaglandin derivative for glaucoma treatment. Bioorganic & Medicinal Chemistry Letters 19, 1639-1642 (2009).
| Cas No. | 1088434-86-9 | SDF | |
| 化学名 | 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl ester, 5Z-heptenoic acid | ||
| Canonical SMILES | O[C@@H]1[C@H](C/C=C\CCCC(OC2=CC=C(C3=CC(SS3)=S)C=C2)=O)[C@@H](CC[C@@H](O)CCC4=CC=CC=C4)[C@H](O)C1 | ||
| 分子式 | C32H38O5S3 | 分子量 | 598.8 |
| 溶解度 | ≤2mg/ml in ethanol;20mg/ml in DMSO;30mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.67 mL | 8.35 mL | 16.7001 mL |
| 5 mM | 0.334 mL | 1.67 mL | 3.34 mL |
| 10 mM | 0.167 mL | 0.835 mL | 1.67 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。